Login to Your Account

FDA Advisory Committee Votes In Favor of Chelsea's Northera

By Ronald A. Rader
Contributing Writer

Friday, February 24, 2012
The Cardiovascular and Renal Drugs Advisory Committee (CRDAC), voted Thursday 7-4, with one abstention and much uncertainty, in favor of the FDA approving Northera from Chelsea Therapeutics International Inc. for treating neurogenic orthostatic hypertension (NOH) in patents with primary autonomic failure due to conditions such as Parkinson's disease, multiple system atrophy and pure autonomic failure, dopamine beta hydroxylase deficiency and nondiabetic autonomic neuropathy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription